Shares of NeuroOne Medical Technologies jumped 13.5% to $1.93 on Thursday, extending a rally fueled by real-world clinical evidence from Mayo Clinic showing its brain ablation system delivered meaningful seizure reduction in epilepsy patients — a dataset that gives the micro-cap its strongest clinical validation to date. The question now: whether a company with minimal revenue can convert promising hospital data into a durable business. NeuroOne Rides Mayo Clinic Epilepsy Data to a 13.5% Pop — but Can a Company Burning Cash at This Rate Turn Buzz Into a Business?
Shares of NeuroOne Medical Technologies surged 13.5% to $1.93, extending follow-through buying after real-world clinical data from Mayo Clinic showed its brain ablation system significantly reduced seizure frequency in drug-resistant epilepsy patients. For a company with a market capitalization hovering near just $17 million, the stakes of any single data readout are outsized — and so are the risks.
• Mayo Clinic Data Hits at the Right Time, but the Formal Registry Is Still Getting Started. The ablation system is the first and only FDA-cleared device that can both record brain signals and destroy diseased brain tissue in one procedure, eliminating the need for multiple surgeries. The Mayo Clinic physician-experience dataset — showing improved seizure outcomes and no serious long-term complications — gives doctors a reason to adopt. But NeuroOne's formal post-market real-world evidence registry was only registered in April 2026 and has not yet begun recruiting patients , meaning rigorous, large-scale proof is still years away.
• Revenue Is Growing Fast From a Tiny Base — and the Company Is Still Losing Money. Product revenue for the brain ablation system grew 72% year-over-year to $2.4 million in Q2 fiscal 2026.
Full-year guidance stands at $10.5 million, excluding potential new product launches. But the company posted a net loss of $2.1 million last quarter, and cash on hand shrank to just $2.8 million from $6.6 million six months earlier.
Management has said it can fund operations only through the end of its fiscal year ending September 2026 — meaning a capital raise or partnership deal is almost certainly coming.
• Zimmer Biomet Distribution Is the Lever, but Visibility Is Limited. Zimmer holds exclusive global distribution rights for the company's electrodes and ablation devices , giving NeuroOne access to a massive sales force it could never afford alone. Yet the company has acknowledged it lacks detailed data on how many hospitals Zimmer has actually placed the product in , a notable transparency gap for investors trying to model growth.
• The Bigger Picture: A $50 Million Patient Population Meets a Sub-$20 Million Company. Roughly 50 million people globally are affected by epilepsy , with a third resistant to drugs. NeuroOne already had to restate Q1 2026 financials after a $0.5 million revenue overstatement , denting credibility. With earnings due August 19, investors are betting that Mayo Clinic's stamp of approval will accelerate sales — but the cash runway leaves almost no room for execution missteps.